... tosylate, and decynium 22 were provided by Bayer HealthCare AG (Wuppertal,
Germany). ... The Km and Vmax values were obtained by fitting the Michaelis-
Menten ..... Sorafenib, a P-gp and Bcrp substrate (Hu et al., 2009; Gnoth et al.,
2010; .... American Association of Pharmaceutical Scientists Annual Meeting;
SCH., ET AL. 98-1768 BUCKMAN COMPANY V. PLAINTIFF'S LEGAL
COMMITTEE 98-1836 U. S. HEALTHCARE SYSTEMS, PA V. PA HOSP. INS. CO.
, ET AL.
... saturable with a Michaelis-Menten constant of 3.80 ± 2.53 µM and a Vmax of
116 ± 42 pmol/mg/min. ... of sorafenib occur within 2 to 3 hours after a single oral
dose (Strumberg et al., ... decynium 22 were provided by Bayer HealthCare AG (
Wuppertal, Germany). ...... Ming X,; Ju W,; Wu H,; Tidwell RR,; Hall JE,; Thakker
Jul 4, 2013 ... (v) Role of Interactions among OCT1 Substrates in Liver Pharmacology. ... J.
Bruix, J. L. Raoul, M. Sherman et al., “Efficacy and safety of sorafenib in .... O. Briz
, M. J. Monte, A. G. Blazquez, and R. I. R. Macias, “Genetic variants in .... as a
fluorescent probe substrate,” Journal of Pharmaceutical Sciences, vol.
Oct 28, 2014 ... <sup>1</sup> p < 0.017 compared to CONT LFD.<sup>2</sup> p < 0.017 compared to CONT HFD.<sup>3</sup> p <
0.017 HFD vs. ... version 188.8.131.52 (Philips Healthcare, Andover, MA, USA) whole
body scanner ... (GC/MS) using the procedure detailed by D. Milatovic et al. .....
Utzschneider, K.M.; Bayer-Carter, J.L.; Arbuckle, M.D.; Tidwell, J.M.; .....
These compounds continue to be examined in preclinical studies (R. Tidwell,
UNC, ... In more recent work, Gilbert et al. identified trimethoprim analogs that are
.... 1 and phase 2 studies under the auspices of MMV and industrial partner Bayer
. .... Few in the pharmaceutical industry viewed kinases as viable targets until the
Gut microbiota plays an important role for animal health, performance, and
product safety (Torok et al., 2011). Interest in finding an effective and
Jul 18, 2011 ... supplied by from Mepha Pharma AG (Aesch, BL, Switzerland), and mefloquine.
101 ... levoflaxin (Aventis, Meyrin, Switzerland), 20 µg/ml ciprofloxacin (Bayer,
Zürich,. 109 ... Treatments were carried out as described in Stadelmann et al. (47)
. ..... Gelmedin, V., R. Caballero-Gamiz, and K. Brehm. 2008.
United States Department of Justice's PlainSite profile, including litigation,
intellectual property, public records and more.
The effects of aerobic training vs. resistance training also have been debated.
Several studies .... Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of